159 related articles for article (PubMed ID: 19582579)
1. Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
Kovacs TO; Freston JW; Haber MM; Atkinson S; Hunt B; Peura DA
Dig Dis Sci; 2010 May; 55(5):1325-36. PubMed ID: 19582579
[TBL] [Abstract][Full Text] [Related]
2. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
Peura DA; Freston JW; Haber MM; Kovacs TO; Hunt B; Atkinson S
Dig Dis Sci; 2009 May; 54(5):955-63. PubMed ID: 18726153
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
[TBL] [Abstract][Full Text] [Related]
7. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
[TBL] [Abstract][Full Text] [Related]
8. Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.
Mathias SD; Colwell HH; Miller DP; Pasta DJ; Henning JM; Ofman JJ
Dig Dis Sci; 2001 Nov; 46(11):2416-23. PubMed ID: 11713946
[TBL] [Abstract][Full Text] [Related]
9. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
10. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.
Wyrwich KW; Mody R; Larsen LM; Lee M; Harnam N; Revicki DA
Qual Life Res; 2010 May; 19(4):551-64. PubMed ID: 20195905
[TBL] [Abstract][Full Text] [Related]
11. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Kovacs TO; Freston JW; Haber MM; Hunt B; Atkinson S; Peura DA
Dig Dis Sci; 2009 Aug; 54(8):1693-701. PubMed ID: 19267194
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
[TBL] [Abstract][Full Text] [Related]
14. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Haber MM; Hunt B; Freston JW; Peura DA; Kovacs TO; Atkinson S; Hisada M
Aliment Pharmacol Ther; 2010 Jul; 32(1):83-96. PubMed ID: 20345509
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
16. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Russo A; Dattilo M
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
[TBL] [Abstract][Full Text] [Related]
17. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Brunner G; Arnold R; Hennig U; Fuchs W
Aliment Pharmacol Ther; 1993; 7 Suppl 1():51-5, discussion 61-6. PubMed ID: 8490080
[TBL] [Abstract][Full Text] [Related]
18. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
19. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
20. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD; Scott LJ
Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
